Liquid Biopsy Market Size is Anticipated to Reach USD 33.45 Billion by 2035

According to a recently published report by Roots Analysis, the growing adoption of liquid biopsy solutions among patients and healthcare providers, is driven by their ability to offer non-invasive, early, and real-time cancer detection with improved accuracy and accessibility.

Global Liquid Biopsy Market Overview

The global liquid biopsy market is expected to reach USD 33.45 billion by 2035, growing at a CAGR of 15.0% during the forecast period till 2035.  

The past decade has witnessed substantial innovation in liquid biopsy platforms and regulatory approvals of minimally invasive blood based liquid biopsy tests. Liquid biopsies are modified blood tests that can detect the presence of circulating markers in the blood from the primary tumor and the sites to which the tumor has metastasized. It is a non-invasive diagnostic procedure where, instead of removing pieces of tissue from the tumor, doctors use the blood drawn from a patient to not only identify the clinicopathological stage of cancer but also predict whether the cancer is metastasizing to other parts of the body. In the coming years, liquid biopsy solutions are set to transform cancer care by enabling earlier detection, more personalized treatments, and real-time monitoring of treatment response.

Browse 160+ figures and ~130 market data tables and detailed Table of Content on “Distribution by Type of Technology ( Next-Generation Sequencing and Polymerase Chain Reaction), Type of Sample (Blood, Other Samples), Type of Circulating Biomarker (Circulating Tumor DNA, Cell Free DNA, Cell Free RNA, Exosomes, Other Circulating Biomarkers), Type of Cancer (Breast Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Bladder Cancer, Melanoma, Thyroid Cancer, Gastric Cancer, Head and Neck Cancer, Leukemia, Brain Cancer, Liver Cancer, Cervical Cancer, Ovarian Cancer, Oesophagus Cancer, Pancreatic Cancer, Nasopharyngeal Cancer, and Sarcoma), Application Area (Early Diagnosis, Patient Monitoring, Recurrence Monitoring), End-user (Hospitals / Laboratories, Research Institutes, Other End-users), and Geographical Regions (North America, Europe, and Asia-Pacific) here: https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html

Market Drivers

Liquid biopsy market growth is being propelled by several factors. A primary driver is the rising global incidence of cancer, which has intensified the demand for efficient, minimally invasive diagnostic tools that can facilitate early detection and continuous patient monitoring. Further, significant advancements in next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) have enhanced the sensitivity and accuracy of these assays, allowing for the precise identification of ctDNA and other biomarkers. This technological evolution, coupled with an increasing shift toward precision medicine and personalized therapeutic strategies, has bolstered clinical adoption. Consequently, the ability of liquid biopsies to provide real-time insights into tumor dynamics without the complications of traditional tissue biopsies is fostering substantial investment and commercial interest across the healthcare sector.

Market Restraints

Liquid biopsy market size is expanding significantly, but there are several obstacles that could prevent the sector from expanding. The high cost of advanced sequencing technologies and specialized equipment remains a barrier for many diagnostic laboratories and smaller healthcare facilities. The market also faces hurdles related to inconsistent reimbursement policies and a complex regulatory landscape, as many liquid biopsy testing solutions still lack the comprehensive clinical validation required to replace traditional tissue biopsies as the gold standard. Further, these factors are limiting wider adoption and can restrict market growth for liquid biopsy.

Growth Factors

Despite the restraints, there are various factors that help the market grow at a steady pace. One notable factor is rising integration of artificial intelligence and machine learning in genomic data analysis, which has significantly improved the ability to distinguish subtle cancer signals from biological noise. Further, the expanding application of liquid biopsy beyond oncology, specifically in non-invasive prenatal testing (NIPT), organ transplant rejection monitoring, and infectious disease diagnostics is creating new and diverse revenue opportunities. The market also benefits from a surge in strategic collaborations between pharmaceutical companies and diagnostic developers to create companion diagnostics that streamline drug development and patient selection for clinical trials.

Liquid Biopsy Market Segments

Based on the type of technology, the market is segmented into next-generation sequencing and polymerase chain reaction.

• The next-generation sequencing segment captures the largest revenue share of nearly 50% in the liquid biopsy market, in 2026.
• The next-generation sequencing segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 17.1% during the forecast period.

Based on the type of sample, the market is segmented into blood and other samples.

• Blood segment captures the largest revenue share of ~90% in the liquid biopsy market, in 2026 and is likely to grow at a notable growth rate during the forecast period.
• Other samples is also anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 18.2% during the forecast period.

Based on the type of circulating biomarker, the market is segmented into circulating tumor DNA, cell free DNA, cell free RNA, exosomes, and other circulating biomarkers.

• In 2026, circulating tumor DNA segment is likely to capture majority of the market share (about 45%), and this trend is unlikely to change in the future as well.
• The exosomes segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 16.5% during the forecast period.

Based on the type of cancer, the market is segmented into breast cancer, colorectal cancer, prostate cancer, lung cancer, bladder cancer, melanoma, thyroid cancer, gastric cancer, head and neck cancer, leukemia, brain cancer, liver cancer, cervical cancer, ovarian cancer, oesophagus cancer, pancreatic cancer, nasopharyngeal cancer, and sarcoma.

• The breast cancer segment captures the largest revenue share of about 30% in the liquid biopsy market, in 2026.
• The nasopharyngeal cancer segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 15.8% during the forecast period.

Based on the application area, the market is segmented into early diagnosis, patient monitoring, and recurrence monitoring.

• Early diagnosis segment captures the largest revenue share of ~70% in the liquid biopsy market, in 2026 and is likely to grow at a notable growth rate during the forecast period.
• Notable, early diagnosis segment is also anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 15.7% during the forecast period.

Based on the end-user, the market is segmented into hospitals / laboratories, research institutes, and other end-users.

• In 2026, hospitals / laboratories segment is likely to capture majority of the market share (about 75%), and this trend is unlikely to change in the future as well.
• Hospitals / laboratories segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 15.7% during the forecast period.

Based on geographical regions, the market is segmented North America, Europe and Asia-Pacific

• North America dominated the liquid biopsy market and is likely to account for the largest revenue share of around 50% in 2026.
• The market in Asia-Pacific is expected to grow at the highest CAGR of 17.8% during the forecast period.

Key Companies Profiled

The liquid biopsy market report also includes detailed profiles of key players (listed below) that offer these products:

• Amoy Diagnostics
• Biocartis
• DiaCarta
• Exact Sciences
• Gencurix
• GeneCast Biotechnology
• Integrated DNA Technologies
• Lucence
• MedGenome
• Medicover Genetics
• nRICH dx
• Precipio
• QIAGEN
• RGCC Group
• Screen Cell
• Singlera Genomics
• Thermo Fisher Scientific

You Can Download Free Sample PDF Copy of this Report at: https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research/ consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com